Fonar Announces Financial Results for Fiscal 2021 as Diluted EPS Increases 23%
- Total MRI scan volume at the HMCA-managed sites increased 7 % to 178,364 scans for the fiscal year ending June 30, 2021 as compared to the prior year.
- Total Revenues-Net increased by 5% to $89.9 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.
- Income from Operations increased 25% to $17.1 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.
- Net Income increased 17% to $13.7 million for the fiscal year ended June 30, 2021 versus the previous fiscal year.
- Diluted Net Income per Common Share increased 23% to $1.45 for the fiscal year ended June 30, 2021 versus the previous fiscal year.
- Book Value Per Share increased by 6% to $20.41 per share. Working Capital increased by 15% to $88.5 million at June 30, 2021.
- Cash and cash equivalents and short term investments increased 21% to $44.5 million at June 30, 2021 versus the fiscal year ended June 30, 2020.
- The 39th HMCA-managed MRI scanner was acquired in West Yonkers, NY during the last quarter of Fiscal 2021.
Melville, New York--(Newsfile Corp. - September 28, 2021) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported today its fiscal 2021 results. FONAR's primary source of income is attributable to its wholly-owned diagnostic imaging management subsidiary, Health Management Company of America (HMCA). In 2009, HMCA managed 9 MRI scanning centers equipped with 9 MRI scanners. Currently, HMCA manages scanning centers in New York and Florida collectively equipped with 39 MRI scanners.
Effective April 27, 2020, the Securities and Exchange Commission issued a Final rule, Release No. 34-88365. Among the changes was that a smaller reporting company meeting an annual revenue threshold of under $100 million, such as FONAR, would no longer be an accelerated filer. Therefore, FONAR's 10-K is due 90 days after the end of its fiscal year and 10-Qs are due 45 days after the end of each fiscal quarter.
Total Net revenues increased by 5% to $89.9 million for the fiscal year ended June 30, 2021, as compared to $85.7 million for the fiscal year ended June 30, 2020.
Total Costs and Expenses for the fiscal year ended June 30, 2021 increased by 1% to $72.8 million, as compared to $72.0 million for the fiscal year ended June 30, 2020.
Revenues from the management of the diagnostic imaging center segment, consisting of patient fee revenue net of contractual allowances and discounts, and management and other fees of related and non-related medical practices, increased to $80.9 million for the fiscal year ended June 30, 2021, as compared to $77.2 million for the fiscal year ended June 30, 2020.
Revenues from product sales and upgrades and service and repair fees for related and non-related medical parties, for the fiscal year ended June 30, 2021 increased by 6% to $9.0 million, as compared to $8.5 million for the fiscal year ended June 30, 2020.
Research and Development expenses decreased 19% to $1.6 million, for the fiscal year ended June 30, 2021, as compared to $2.0 million for the fiscal year ended June 30, 2020. The reasons for the decrease in R&D include supply chain related delivery delays, due to the COVID-19 pandemic.
Selling, general and administrative (S,G&A) expenses decreased 7% to $24.7 million for the fiscal year ended June 30, 2021 as compared to $26.7 million for the fiscal year ended June 30, 2020. This decrease was due to service contracts, management fees and other receivables impacted by the COVID-19 pandemic in the prior fiscal year.
Income from Operations increased 25% to $17.1 million for the fiscal year ended June 30, 2021, as compared to $13.7 million for the fiscal year ended June 30, 2020.
Net Income increased 17% to $13.7 million, for the fiscal year ended June 30, 2021, as compared to $11.7 million for the fiscal year ended June 30, 2020.
Diluted Net Income per Common Share available to common shareholders increased 23% to $1.45, for the fiscal year ended June 30, 2021, as compared to $1.18 for the fiscal year ended June 30, 2020.
The weighted average diluted shares outstanding -common stockholders for the fiscal year ended June 30, 2021 increased 1% to 6.63 million versus 6.57 million for the fiscal year ended June 30, 2020.
Balance Sheet Items
Total Cash and Cash Equivalents and Short Term Investments at June 30, 2021 increased 21% to $44.5 million as compared to the $36.8 million at June 30, 2020.
Total Assets at June 30, 2021 were $189.5 million as compared to $180.3 million at June 30, 2020.
Total Liabilities at June 30, 2021 were $54.1 million as compared to $54.0 million at June 30, 2020.
The ratio of Total Assets / Total Liabilities increased 5% to 3.5 at June 30, 2021 as compared to 3.3 at June 30, 2020.
Total Current Assets at June 30, 2021 were $108.6 million as compared to $95.9 million at June 30, 2020.
Total Current Liabilities at June 30, 2021 were $20.0 million as compared to $18.7 million at June 30, 2020.
Working Capital increased 15% to $88.5 million at June 30, 2021 as compared to $77.2 million at June 30, 2020.
Net Book Value per Common Share increased 6% to $20.41 at June 30, 2021 as compared to $19.21 at June 30, 2020, one year ago.
Cash Flow Item
Operating Cash Flow was $19.1 million for the fiscal year ended June 30, 2021 as compared to $20.4 million for the fiscal year ended June 30, 2020.
During the fiscal year, the 36th HMCA-managed MRI scanner became operational in Pembroke Pines, Florida. Islandia, New York became the 37th MRI scanner in the HMCA managed network. The 38th HMCA-managed MRI scanner became operational at the White Plains, New York scanning center. Finally, the 39th MRI was acquired at a Stand-Up® MRI facility in Yonkers, New York. There are now two locations in Yonkers, each on the other side of that town. The extra location nicely expands and strengthens the Company's presence in Westchester County. FONAR's subsidiary HMCA now has 39 MRI scanners under its management as compared to 36 scanners one year ago.
On March 9, 2021, FONAR rang the Nasdaq Stock Market Closing Bell, to celebrate the 50th birthday of MRI. Fifty years ago, in March 1971, the widely-read journal Science published "Tumor Detection by Nuclear Magnetic Resonance" by FONAR founder and chairman Dr. Raymond V. Damadian. This journal article explained Dr. Damadian's discovery that there is a marked difference in the relaxation time of the NMR (MRI) signals between normal and cancerous tissues of the same type, as well as between different types of normal tissues.
Nasdaq Headquarters, Times Square, New York, NY
To view an enhanced version of this graphic, please visit:
Soon scientists around the world began repeating his experiment to learn for themselves about his discovery. They often cited his works in their own peer reviewed publications and Dr. Damadian's publication in Science is often referred to as the beginning of MRI.
Dr. Damadian said, "I got my first idea for MRI in 1969, and in 1970 made the discovery that is the basis for the making of every MRI image ever produced and the foundation of the MRI industry. The discovery resulted in the generation of the pronounced pixel contrast that was deficient in traditional medical imaging technology (X-ray, CT, 4%) and was needed for adequate visualization of the body's vital organs and assessment of their well-being. The discovery raised the pixel contrast of medical imaging, and the pronounced elaboration of image detail it generates to 131%."
As reported in edubilla.com: "But without this discovery of the profound sensitivity of the relaxation time to different tissue types and malignant tissue THERE WOULD BE NO PICTURE AT ALL."
Dr. Damadian's discovery, as reported in Science 1971, soon led to the first patent application in MRI in 1972.
On July 3, 1977 Dr. Damadian, with his two post doctorate students, Lawrence Minkoff, Ph.D., and Michael Goldsmith. Ph.D., made the world's first MRI scan on the first ever MRI scanner they built and named 'Indomitable.'
Dr. Damadian began FONAR, the world's first dedicated MRI Company in 1978, and the Company installed the world's first commercial MRI in 1980.
In 1981, FONAR became a NASDAQ-listed company and 40 years later has delightedly marked the 50th anniversary of the birth of MRI by ringing the Nasdaq Stock Market Closing Bell.
Timothy R. Damadian, President and CEO, said, "A proper assessment of HMCA's performance in fiscal 2021 must take into consideration the company's experience in fiscal 2020. The total scan volume in the first three quarters of fiscal 2020 was 2% higher than we achieved in first three quarters of the prior year. We were doing fine; then came COVID-19, posing the greatest challenge our company has ever faced. The pandemic took its greatest toll on our business in the fourth quarter, where scan volume fell to nearly half of what it was in fourth quarter of the prior year, leaving us with a 17,000 decrease in scan volume, a 9% decrease, for the full fiscal year compared to the year before."
"The effects of the pandemic continued into fiscal 2021, but we have been steadily recovering. I am pleased to report that total scan volume of 178,000 at HMCA-managed sites in fiscal 2021 was 7% higher than we achieved in the prior year; our fourth quarter scan volume of 47,800 scans was our best ever; and we reached 97% of the scan volume achieved in pre-COVID fiscal 2019. I am grateful to my management team, the non-controlling-interest group members, and all HMCA employees for this accomplishment."
Mr. Damadian continued, "Even though we were in recovery mode in fiscal 2021, we added a second MRI at our Islandia site on Long Island, New York in October 2020, a second MRI at our White Plains site in Westchester County, New York in January 2021; and in March 2021 acquired a fully operational MRI facility in Yonkers, also in Westchester County, across town from our existing Yonkers facility. So by June 30, 2021 HMCA was managing 39 MRI scanners at 27 locations in New York and Florida.
"For fiscal 2022, we're looking at four major projects. By the end of the first half of fiscal 2022 we plan to have completed the installation of a second MRI scanner at our Pembroke Pines, Florida site, established another MRI facility in the Bronx, New York, and relocated one of our Manhattan, New York facilities across town where it will be equipped with two MRI scanners. In the second half of fiscal 2022, we plan to establish a new facility in central Florida."
"The prime focus of the selection of scanning center locations is that they will be financially very successful. Our team has an excellent understanding of the nuances of this medical market place. So, these four new centers in fiscal 2022 are a 10 percent increase in the number of centers that we manage and we expect that this will translate into a corresponding increase in revenues and profitability," concluded Mr. Damadian.
FONAR Founder and Chairman of the Board, Raymond V. Damadian, M.D., said, "It is encouraging to see over the last year and a half how HMCA has skillfully met the challenges posed by the COVID-19 pandemic. By the end of fiscal 2021, HMCA-managed sites were nearly back to pre-COVID levels; the HMCA network was both strengthened and expanded to facilitate future growth; and FONAR has remained profitable throughout. HMCA's success is a testimony to its highly experienced and competent management team and its employees, and the enduring appeal of the FONAR UPRIGHT® Multi-Position™ MRI (also known as the STAND-UP® MRI) among patients and physicians."
"MRI is the most powerful imaging modality ever developed," said Dr. Damadian. "This is due to the exceptional pixel contrast generated by the MRI image and the exceptional image detail it generates. The maximum pixel contrast available from x-ray technology (e.g. CT) is 4%, as compared to the 131% detail generating pixel contrast available by MRI. This wide spectrum of pixel contrast allows for the visualization of all parts of the body at an unprecedented level of detail in medical imaging. It includes the vital soft tissues of the body which are essentially not visualized in the same level of any detail in any other imaging modalities. This pixel contrast gives the MRI image its sharp and revealing image quality."
"The discovery of (pixel) contrast between different healthy tissue types and cancer was the important discovery made that was published in the Journal 'Science' in March, 1971. It was very pleasing to us at FONAR Corporation that the 50th anniversary of the publishing of our 1971 Science Journal article was recognized by NASDAQ at NASDAQ's 'Ring the Closing Bell' ceremony this past March," added Dr. Damadian.
"The other important feature of the UPRIGHT® MRI is that it is the only MRI that can image the patient in the fully weight-bearing position. Physicians recognize how the diagnostic information obtained from having their patients scanned in fully weight-bearing positions, such as sitting, bending or standing, can lead to more effective treatments that result in better patient outcomes. Scanning patients in these positions is possible only on the patent-protected FONAR UPRIGHT® Multi-Position™ MRI. It is well known that the majority of MRI studies are of the spine, and it is widely reported that about 80% of adults experience low back pain at some point in their lifetimes. This is critical in explaining the reasons for our past success and our very promising future."
Dr. Damadian continued, "Unfortunately, COVID-19 has slowed our R&D progress on MRI imaging of cerebrospinal fluid (CSF) flow and its impact on the cerebral neurodegenerative diseases. Our research is focused on quantifying the CSF and measuring its cc's of flow and velocity as it circulates through the head, neck and spine. We've been able to use quantitative CSF data collected from asymptomatic patients to identify the degree to which CSF flow impairment is responsible for the patient's symptoms and the degree to which the patient's surgical or non-surgical CCJ treatment can restore the patient's critical brain and central nervous symptom's to normal. We use the FONAR UPRIGHT® MRI to visualize the fluid (CSF) as it flows up and down the neck and around the brain and then quantify the visualized CSF flow. We are also hopeful that our research may lead to a new understanding of the role the CSF plays in the neurologic diseases MS, Parkinson's disease, Alzheimer's and childhood autism."
Dr. Damadian concluded, "Although the COVID-19 is still with us, there are many signs that the economy is returning to normal. Our scanning centers are near their pre-COVID levels and we believe that soon they will surpass them."
FONAR, the Inventor of MR Scanning™, located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. FONAR's signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often detects patient problems that other MRI scanners cannot because they are lie-down, "weightless-only" scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while watching TV.
FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body's neurologic system has been made possible first by FONAR's introduction of the MRI and now by this latest works-in-progress method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among those who will benefit from this new understanding.
FONAR's primary source of income and growth is attributable to its wholly-owned diagnostic imaging management subsidiary, Health Management Company of America (HMCA) www.hmca.com.
FONAR's substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring the Upright cerebral hydraulics of the cerebro-spinal fluid (CSF) of the central nervous system. FONAR's UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.
UPRIGHT® and STAND-UP® are registered trademarks. The Inventor of MR Scanning™, CSP™, Multi-Position™, UPRIGHT RADIOLOGY™, The Proof is in the Picture™, pMRI™, CSF Videography™, and Dynamic™ are trademarks of FONAR Corporation.
This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.
The Inventor of MR Scanning™
An ISO 9001 Company
Melville, New York 11747
Phone: (631) 694-2929
Fax: (631) 390-1772
FONAR CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
|Cash and cash equivalents||$||44,460,411||$||36,802,342|
|Short term investments||32,177||31,884|
|Accounts receivable - net of allowances for doubtful accounts of $442,270 and $514,561 at June 30, 2021 and 2020, respectively||4,525,435||4,312,999|
|Accounts receivable - related party||11,977||5,988|
|Medical receivables - net||17,900,489||16,171,782|
|Management and other fees receivable - net of allowances for doubtful accounts of $15,786,878 and $11,063,233 at June 30, 2021 and 2020, respectively||30,947,863||27,437,768|
|Management and other fees receivable - related party medical practices - net of allowances for doubtful accounts of $4,184,399 and $3,322,055 at June 30, 2021 and 2020, respectively||7,814,250||6,896,482|
|Costs and estimated earnings in excess of billings on uncompleted contracts||-||152,833|
|Income tax receivable||-||671,185|
|Prepaid expenses and other current assets||1,227,463||1,757,499|
|Total Current Assets||108,583,484||95,889,532|
|Accounts receivable - long term||2,879,946||2,730,071|
|Deferred income tax asset||15,958,961||18,809,757|
|Property and equipment - net||21,850,139||21,364,034|
|Right-of-use-asset - operating leases||30,133,285||31,392,458|
|Right-of-use-asset - financing lease||1,126,990||1,325,870|
|Other intangible assets - net||4,037,599||4,109,129|
FONAR CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
|Current portion of long-term debt and capital leases||$||173,206||$||108,379|
|Other current liabilities||9,162,118||8,185,098|
|Operating lease liability - current portion||3,533,656||3,370,149|
|Financing lease liability - current portion||202,741||74,699|
|Unearned revenue on service contracts||4,365,825||4,105,265|
|Billings in excess of costs and estimated earnings on uncompleted contracts||14,739||-|| |
|Total Current Liabilities||20,049,421||18,663,428|
|Unearned revenue on service contracts||2,800,522||2,655,605|
|Deferred income tax liability||238,316||234,106|
|Due to related party medical practices||92,663||92,663|
|Operating lease liability - net of current portion||28,975,132||30,104,464|
|Financing lease liability - net of current portion||1,048,431||1,251,171|
|Long-term debt and capital leases, less current portion||760,254||865,416|
|Other liabilities||171,331||150,311|| |
|Total Long-Term Liabilities|| ||34,086,649||35,353,736|| |
FONAR CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
|Class A non-voting preferred stock $.0001 par value; 453,000 shares authorized at June 30, 2021 and 2020, 313,438 issued and outstanding at June 30, 2021 and 2020||$||31||$||31|
|Preferred stock $.001 par value; 567,000 shares authorized at June 30, 2021 and 2020, issued and outstanding - none||-||-|
|Common stock $.0001 par value; 8,500,000 shares authorized at June 30, 2021 and 2020, 6,565,853 and 6,459,106 issued at June 30, 2021 and 2020, respectively; 6,554,210 and 6,447,463 outstanding at June 30, 2021 and 2020, respectively||657||647|
|Class B convertible common stock (10 votes per share) $.0001 par value; 227,000 shares authorized at June 30, 2021 and 2020, 146 issued and outstanding at June 30, 2021 and 2020||-||-|
|Class C common stock (25 votes per share) $.0001 par value; 567,000 shares authorized at June 30, 2021 and 2020, 382,513 issued and outstanding at June 30, 2021 and 2020||38||38|
|Paid-in capital in excess of par value||185,100,976||183,076,888|
|Treasury stock, at cost - 11,643 shares of common stock at June 30, 2021 and 2020|| ||(675,390||)|| ||(675,390||)|
|Total Fonar Corporation's Stockholders' Equity||138,418,649||126,186,963|
|Noncontrolling interests|| ||(3,048,524||)|| ||55,253|| |
|Total Stockholders' Equity|| ||135,370,125|| || ||126,242,216|| |
|Total Liabilities and Stockholders' Equity||$||189,506,195|| ||$||180,259,380|| |
FONAR CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
|For the Years Ended June 30,|
|Patient fee revenue, net of contractual allowances and discounts||$||23,307,389||$||22,495,260|
|Product sales - net||1,288,483||297,613|
|Service and repair fees - net||7,638,608||8,055,490|
|Service and repair fees - related parties - net||110,000||110,000|
|Management and other fees - net||46,609,449||44,565,405|
|Management and other fees - related party medical practices - net|| ||10,975,836|| ||10,166,694|| |
|Total Revenues - Net|| ||89,929,765|| ||85,690,462|| |
|Costs and Expenses|
|Costs related to product sales||1,032,676||745,375|
|Costs related to service and repair fees||2,740,625||2,731,397|
|Costs related to service and repair fees - related parties||39,466||37,298|
|Costs related to patient fee revenue||10,917,635||10,880,265|
|Costs related to management and other fees||25,384,557||22,951,301|
|Costs related to management and other fees - related party medical practices||6,341,168||5,951,189|
|Research and development||1,635,979||2,025,376|
|Selling, general and administrative, inclusive of compensatory element of stock issuances of $83,277 and $0 for the years ended June 30, 2021 and 2020 respectively|| ||24,740,044|| ||26,717,345|| |
|Total Costs and Expenses|| ||72,832,150|| ||72,039,546|| |
|Income from Operations||17,097,615||13,650,916|
|Other Income and (Expenses):|
|Other income|| ||504,450|| ||70,771|| |
|Income before provision for income taxes and noncontrolling interests||17,665,331||14,149,511|
|Provision for Income Taxes|| ||(3,991,520||)|| ||(2,444,778||)|
|Net Income - Noncontrolling Interests|| ||(3,466,223||)|| ||(3,464,528||)|
|Net Income - Attributable to FONAR||$||10,207,588||$||8,240,205|
FONAR CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME (Continued)
|Net Income Available to Common Stockholders||$||9,592,134||$||7,735,650|
|Net Income Available to Class A Non-Voting Preferred Stockholders||$||458,710||$||376,055|
|Net Income Available to Class C Common Stockholders||$||156,744||$||128,500|
|Basic Net Income Per Common Share Available to Common Stockholders||$||1.47||$||1.20|| |
|Diluted Net Income Per Common Share Available to Common Stockholders||$||1.45||$||1.18|
|Basic and Diluted Income Per Share - Class C Common||$||0.41||$||0.34|
|Weighted Average Basic Shares Outstanding - Common Stockholders||6,505,283||6,443,713|
|Weighted Average Diluted Shares Outstanding - Common Stockholders||6,632,787||6,571,217|
|Weighted Average Basic and Diluted Shares Outstanding - Class C Common||382,513||382,513|
FONAR CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
|For the Years Ended June 30,|
|CASH FLOWS FROM OPERATING ACTIVITIES|
|Adjustments to reconcile net income to net cash provided by operating activities:|
|Depreciation and amortization||4,081,687||3,908,648|
|Provision for bad debts||5,585,989||5,695,420|
|Deferred income tax - net||2,855,006||2,118,829|
|Income tax receivable||671,185||528,815|
|Amortization on right-of-use assets||1,458,053||1,005,560|
|Compensatory element of stock issuances||83,277||-|
|Stock issued for costs and expenses||1,940,821||1,990,380|
|(Increase) decrease in operating assets, net:|
|Accounts, medical and management fee receivables||(12,110,859||)||(10,797,456||)|
|Costs and estimated earnings in excess of billings on uncompleted contracts||152,833||372,277|
|Prepaid expenses and other current assets||526,425||(133,287||)|
|Increase (decrease) in operating liabilities, net:|
|Other current liabilities||1,382,497||3,556,437|
|Operating lease liabilities||(965,825||)||159,657|
|Financing lease liabilities||(74,698||)||-|
|Billings in excess of costs and estimated earnings||14,739||-|
|Other liabilities|| ||21,020|| ||115,855|| |
|NET CASH PROVIDED BY OPERATING ACTIVITIES|| ||19,088,001|| ||20,402,763|| |
|CASH FLOWS FROM INVESTING ACTIVITIES|
|Purchases of property and equipment||(3,533,091||)||(7,522,997||)|
|Proceeds of Short term investment||(293||)||15,062,932|
|Purchase of imaging center||(1,122,508||)||-|
|Cost of patents||(163,705||)||(117,522||)|
|NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES||(4,819,597||)||7,422,413|
|CASH FLOWS FROM FINANCING ACTIVITIES:|
|Repayment of borrowings and capital lease obligations||(103,335||)||(4,957,936||)|
|Proceeds from debt||63,000||5,618,089|
|Repayment of notes receivable from employee stockholders||-||-|
|Distributions to noncontrolling interests||(6,570,000||)||(5,565,000||)|
|NET CASH USED IN FINANCING ACTIVITIES||(6,610,335||)||(4,904,847||)|
|NET INCREASE IN CASH AND CASH EQUIVALENTS||7,658,069||22,920,329|
|CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR||36,802,342||13,882,013|
|CASH AND CASH EQUIVALENTS - END OF YEAR||$||44,460,411||$||36,802,342|
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97824